DRI Healthcare Trust (TSE:DHT.UN) Given New C$23.00 Price Target at Canaccord Genuity Group

DRI Healthcare Trust (TSE:DHT.UN) had its target price lifted by investment analysts at Canaccord Genuity Group from C$22.25 to C$23.00 in a research report issued on Tuesday,BayStreet.CA reports. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity Group’s target price suggests a potential upside of 27.71% from the company’s previous close.

A number of other brokerages also recently commented on DHT.UN. Stifel Nicolaus upped their target price on shares of DRI Healthcare Trust from C$23.00 to C$24.00 and gave the stock a “buy” rating in a research note on Tuesday. National Bank Financial boosted their price target on DRI Healthcare Trust from C$22.50 to C$23.50 and gave the company an “outperform” rating in a report on Tuesday, May 19th. Raymond James Financial increased their price objective on DRI Healthcare Trust from C$22.50 to C$23.50 and gave the stock a “strong-buy” rating in a research note on Monday. Finally, Scotiabank lifted their target price on DRI Healthcare Trust from C$25.00 to C$30.00 and gave the company a “sector outperform” rating in a research report on Tuesday, May 19th. One analyst has rated the stock with a Strong Buy rating and four have assigned a Buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of C$24.80.

DRI Healthcare Trust Stock Down 2.7%

DRI Healthcare Trust stock traded down C$0.50 during midday trading on Tuesday, reaching C$18.01. The stock had a trading volume of 45,612 shares, compared to its average volume of 59,601. The firm has a market cap of C$990.84 million, a price-to-earnings ratio of -20.01 and a beta of 0.47. DRI Healthcare Trust has a 52-week low of C$13.24 and a 52-week high of C$19.04. The company has a fifty day moving average of C$17.17 and a 200 day moving average of C$16.64.

DRI Healthcare Trust Company Profile

DRI Healthcare Trust is managed by DRI Capital Inc DRI a pioneer in global pharmaceutical royalty monetization. We provide uniquely favorable exposure for investors in the biopharma industry managing a diversified portfolio of interests in medicines that have a demonstrable positive impact on the world and aiming to acquire dependable patent-protected cash flow streams derived from the sales of those important drugs while limiting the risks and costs connected to drug development. DRI has developed a disciplined strategy predicated on actively sourcing royalty streams on medically necessary products and proudly work with multiple repeat deal partners.DRI Healthcare Trust is an unincorporated open-ended trust governed by the laws of the Province of Ontario pursuant to a declaration of trust dated October 21 2020 as amended.DRI Healthcare Trusts units are listed and trade on the Toronto Stock Exchange under DHT.UN in Canadian dollars and under DHT.U in U.S.